Daily Roundup | Pfizer Adds a Breast Cancer Maintenance Choice & MimiVax's Brain Cancer Vaccine Misses

<p>Pfizer's Tukysa (tucatinib) wins a breast cancer maintenance approval after delaying progression, while MimiVax's SurVaxM misses its overall glioblastoma survival goal despite a younger-patient signal. Halozyme reports an injunction against subcutaneous Keytruda (pembrolizumab) in eight European markets; Caribou said yesterday it plans to halt its two donor CAR-T programs amid financing pressure. Cerevance's investigational solengepras cuts Parkinson's off time by 37 minutes a day beyond placebo. Novartis reports FDA approval of Rhapsido (remibrutinib) for adults with symptomatic dermographism inadequately controlled by H1 antihistamines.</p><p><br /></p><p>Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.</p>